SOURCE-LINKED STUDY SUMMARY
Single Intranasal Administration of the Psychedelic Mebufotenin for Treatment-Resistant Depression: A Randomized Clinical Trial.
Abstract summarizedQuality not appraised
- What was studied
- A phase 2b randomized trial tested intranasal mebufotenin benzoate for treatment-resistant depression.
- Who / model studied
- 193 adults with moderate-to-severe depression after inadequate response to prior antidepressant treatments.
- Studied dose & schedule
- One intranasal dose: 8 mg, 12 mg or 0.3 mg low-dose comparator, with psychological support and antidepressant washout as needed; eight-week follow-up.
- What the study found
- Primary day-29 depression-score difference for 12 versus 0.3 mg: −5.3 MADRS points (95% CI −8.9 to −1.8). Adverse events affected 85% versus 73%; most events across groups were mild or moderate.
- Limitations & context
- Abstract-based assessment. Short follow-up and possible recognition of psychedelic effects limit interpretation. This was not a direct comparison with psilocybin or esketamine and does not establish unsupervised-use safety.
Read summary source ↗ · Prepared 10/28/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1001/jama.2026.18380